Quigley Pharma to Complete Phase IIb Diabetic Peripheral Neuropathy Study
Posted on: Friday, 14 November 2008, 09:00 CST
Quigley Pharma, a wholly-owned subsidiary of The Quigley Corporation, has announced that the last subject in the Phase IIb study is scheduled to complete treatment on November 25, 2008. This will effectively move the study to the final stage of data collection, evaluation and study conclusions, the company said.
The Phase IIb study is designed to evaluate the safety and efficacy of QR-333, a topical formulation designed to offer physicians and patients an effective, easy to administer, safe treatment for diabetic peripheral neuropathy with little to no side effects.
The company believes that a safe and efficacious topical product, if approved by the FDA, could be a 'first line' treatment for diabetic peripheral neuropathy and possibly could develop a significant market position in a growing therapeutic category currently dominated by systemic therapies.
The Phase IIb trial will evaluate the safety and efficacy of QR-333, applied three times daily as compared to placebo-treated patients over 12 weeks. Efficacy will be determined by symptom assessment scores, a visual analogy scale, quality of life and sleep questionnaires. Safety will be determined by medical history, physical examination, vital signs, laboratory tests and nerve conduction studies.
The company, after collecting all the patient information from 21 study centers and conferring with its panel of experts on the data, will draft and report study conclusions, as soon they are available.
Source: Datamonitor
Related Articles
- Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
- Olanzapine Long-Acting Injection (LAI) Efficacy and Safety Data Presented at American Psychiatric Association Annual Meeting
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- IBC Expands Coverage of Case Studies and Projects in Preclinical, Phase 1 and Phase 2
- New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir Vs. Kaletra As Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
- Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
- British Study Confirms Lisinopril Safety
- ADVENTRX Announces Positive Efficacy and Safety Results From CoFactor Phase II Clinical Trial
- First Melanoma Patients Complete Treatment in Provectus Phase 1 Clinical Trial of PV-10
- A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis*
User Comments (0)
RSS Feeds